Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has received a Warning Letter from the USFDA regarding observations on Informed Consent Form (ICF) in a bioequivalence study. The Company believes the Warning Letter does not impose any restriction on its operations and is coordinating with the Clinical Investigator to submit a response within the stipulated timeline.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange about the notice of its 16th Annual General Meeting (AGM) to be held on August 5, 2026, through video conferencing or other audio-visual means. The AGM will consider the business as set out in the notice, including the payment of dividend for the FY 2025-26, if approved. The company has also provided the facility of e-voting through the National Securities Depository Limited (NSDL) for its members.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange regarding the specimen copy of the letter sent to shareholders under Regulation 36(1)(b) of SEBI LODR, and has also announced the 16th Annual General Meeting (AGM) of the company, scheduled to be held on August 5, 2026, through Video Conference facility/ Other Audio Visual Means (VC/OAVM).

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has announced the record date for the payment of dividend for the financial year ended 31st March, 2026, as 29th July, 2026.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange regarding Notice of 16th Annual General Meeting to be held on August 05, 2026. The meeting will consider various resolutions including appointment of a director, dividend declaration, and ratification of remuneration to the cost auditors.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended June 30, 2026.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange about a copy of newspaper publication related to notice of loss of equity share certificate, for claiming shares from IEPF Authority, published by the Company on behalf of the registered shareholder in Indian Express (English Edition) and Financial Express (Gujarati Edition) on 7th July, 2026.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange about the reaffirmation of its credit rating on bank loan facilities and commercial paper by CRISIL Ratings Limited.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has received USFDA Final Approval for Dapsone Gel, 5%, a topical treatment for acne vulgaris.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for dealing in securities of the Company will remain closed from 1st July, 2026 till 48 hours after the declaration of the Unaudited financial results for the quarter ended 30th June, 2026.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has informed the Exchange about a newspaper publication regarding notice of loss of equity share certificate(s) for claiming shares from IEPF Authority.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has received USFDA Final Approval for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL, with an estimated market size of US$ 27 million.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has scheduled a series of one-on-one meetings with institutional investors between June 22 and June 25, 2026. The company's management will engage with prominent funds including HDFC Mutual Fund, Tata Mutual Fund, DSP Mutual Fund, and HDFC Life Insurance Company Limited. These meetings will take place both in-person in Mumbai and virtually. Importantly, Alembic Pharmaceuticals has confirmed that no Unpublished Price Sensitive Information will be shared during these interactions, indicating routine investor relations without new material disclosures.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has scheduled a series of one-on-one investor meetings with prominent financial institutions between June 22 and June 25, 2026. The company's management will meet with HDFC Mutual Fund, Tata Mutual Fund, DSP Mutual Fund, and HDFC Life Insurance Company Limited. These engagements will occur both in-person in Mumbai and virtually via video conferencing. Investors should note that no Unpublished Price Sensitive Information is intended to be shared during these routine interactions with the investment community.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has announced a schedule of one-on-one meetings with prominent institutional investors in June 2026. The company's management will engage with HDFC Mutual Fund, Tata Mutual Fund, DSP Mutual Fund, and HDFC Life Insurance Company Limited on June 22, 23, and 25. These meetings will include both in-person sessions in Mumbai and virtual conferences. Alembic Pharma explicitly stated that no Unpublished Price Sensitive Information will be shared during these interactions. This signifies routine investor relations activity, providing an avenue for management to engage with key stakeholders without disclosing new material information.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited announced it has received a US Food & Drug Administration (USFDA) Tentative Approval for its Binimetinib Tablets, 45 mg. This significant regulatory milestone indicates the company has met the necessary quality and safety standards for the drug. While "tentative," it paves the way for potential future market entry in the United States. For investors, this suggests a future expansion of Alembic's product portfolio and a new revenue opportunity once final approval is obtained and the product is launched.

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited has appointed Mr. Sujit Bhayani as a Non-Executive Independent Director, effective June 18, 2026, for a period of 5 years, subject to shareholder approval.